{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T12:10:02Z","timestamp":1759579802771},"reference-count":52,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2001,12,21]],"date-time":"2001-12-21T00:00:00Z","timestamp":1008892800000},"content-version":"vor","delay-in-days":354,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2001,1]]},"abstract":"<jats:p>Despite our best efforts to deceive the immune system, outwit pathogens, and improve upon the design of nature, there continues to be a need to improve the margin of safety of treatment for those with bleeding disorders. The current approach includes: (1) recombinant factor concentrates free of added proteins; (2) \u2018designer\u2019 factor molecules that enhance function and reduce immunogenicity; and (3) modulation of the immune system to suppress immune response in those who develop inhibitors. The hope is that through advances in our understanding of the coagulation and immune systems, treatment of haemophilia in the new millennium will be safer and less immunogenic. Currently available recombinant clotting factor concentrates include those produced: (1) with pasteurized human serum albumin in the cell culture medium as a stabilizer; (2) with bovine serum proteins in the cell culture medium; and (3) free of plasma derivatives. To the extent that current recombinant clotting factor concentrates contain even trace amounts of human or animal protein, there is continuing potential for transmission of nonenveloped viruses, including hepatitis A and parvovirus, and the theoretical potential for transmission of relatively unknown agents, such as prions (Creutzfeldt\u2013Jakob disease or its variant). Second\u2010generation recombinant factor concentrates that do not use human albumin as a stabilizer are currently in clinical trials, and third\u2010generation recombinant factor concentrates currently in development take advantage of new strategies to achieve a \u2018protein\u2010free\u2019 cell culture, purification, and final formulation. It is likely that improvement in safety and reduction in immunogenicity will require modification not only of antigenic structure but also of the immune response to coagulation proteins.<\/jats:p>","DOI":"10.1046\/j.1365-2516.2001.00097.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T23:06:29Z","timestamp":1047423989000},"page":"28-35","source":"Crossref","is-referenced-by-count":9,"title":["New\u2010generation recombinant factor concentrates: bridge to gene therapy"],"prefix":"10.1111","volume":"7","author":[{"given":"M.V.","family":"Ragni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,21]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-70-4-833"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/scientificamerican0865-88"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196512302732701"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(57)91116-9"},{"key":"e_1_2_8_6_2","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1001\/jama.1972.03200180052024","article-title":"Hepatitis and clotting\u2010factor concentrates.","volume":"221","author":"Kasper CK","year":"1972","journal-title":"JAMA"},{"key":"e_1_2_8_7_2","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1182\/blood.V82.3.1010.1010","article-title":"Presence of antibody to hepatitis C virus (HCV) in hemophilic men with HCV \u2018seroreversion\u2019.","volume":"82","author":"Ragni MV","year":"1993","journal-title":"Blood"},{"key":"e_1_2_8_8_2","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1182\/blood.V70.3.786.786","article-title":"1986 update of HIV seroprevalence, seroconversion, AIDS incidence, and immunologic correlates of HIV infection in patients with haemophilia A and B.","volume":"70","author":"Ragni MV","year":"1987","journal-title":"Blood"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-120-1-199401010-00001"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830390315"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)90065-3"},{"key":"e_1_2_8_12_2","unstructured":"Revised recommendation regarding the use of recombinant clotting factor concentrate therapies. MASAC Recommendation #89.Hemaware1999;4:24\u20137."},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.83.16.5939"},{"key":"e_1_2_8_14_2","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1055\/s-0038-1657535","article-title":"Second generation, B\u2010domain deleted recombinant factor VIII.","volume":"78","author":"Berntorp E.","year":"1997","journal-title":"Thromb Haemost"},{"key":"e_1_2_8_15_2","unstructured":"KesslerCM SpiraJ&FraunhoferA.Safety and efficacy of an albumin\u2010free formulated B\u2010domain deleted recombinant factor VIII (BBD rFVIII rVIII SQ) in previously treated patients (PTPs): a four\u2010year update.Thromb Haemost1999; 472 (Suppl): 1493."},{"key":"e_1_2_8_16_2","unstructured":"LusherJM SpiraJ&RodriguezD.A four\u2010year update of safety and efficacy of an albumin\u2010free formulated B\u2010domain deleted factor VIII (BBD rFVIII rVIII SQ) in previously untreated severe hemophilia A patients.Thromb Haemost1999; 472 (Suppl): 1472."},{"key":"e_1_2_8_17_2","unstructured":"Package insert NovoSevenCoagulation Factor VIIa (Recombinant).Novo Nordisk Pharmaceuticals Inc Princeton NJ1999."},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.00209.x"},{"key":"e_1_2_8_19_2","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1055\/s-0037-1613925","article-title":"Sucrose\u2010formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy: results of a multicenter, international, clinical investigation.","volume":"83","author":"Absire T","year":"2000","journal-title":"Thromb Haemost"},{"key":"e_1_2_8_20_2","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1055\/s-0037-1614918","article-title":"Acute myocardial infarction following administration of recombinant activated factor VII (NovoSeven) in a patient with haemophilia A and inhibitor.","volume":"82","author":"Peerlink K","year":"1999","journal-title":"Thromb Haemost"},{"key":"e_1_2_8_21_2","unstructured":"Package insert BenefixCoagulation Factor IX(Recombinant).Genetics Institute Cambridge MA1997."},{"key":"e_1_2_8_22_2","unstructured":"WhiteG ShapiroA&RagniMet al.Clinical evaluation of recombinant factor IX.Semin Hematol1998;35(Suppl. 2) 33\u20138."},{"key":"e_1_2_8_23_2","unstructured":"ShapiroA AbshireT&GillJet al.Recombinant factor IX (rFIX) in the treatment of previously untreated patients (PUPs) with severe or moderately severe hemophilia B.Thromb Haemost1999; 473 (Suppl.): 1495."},{"key":"e_1_2_8_24_2","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1182\/blood.V89.3.1115","article-title":"Nephrotic syndrome as a complication of immune tolerance in hemophilia B.","volume":"89","author":"Ewenstein BM","year":"1997","journal-title":"Blood"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1996.tb01342.x"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199302183280701"},{"key":"e_1_2_8_27_2","first-page":"37","article-title":"The economics of factor VIII inhibitor treatment.","volume":"31","author":"Lipton RA.","year":"1994","journal-title":"Semin Hematol"},{"key":"e_1_2_8_28_2","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1182\/blood.V69.4.1153.1153","article-title":"A component of factor VIII preparations which can be separated from factor VIII activity down\u2010modulates human monocyte functions.","volume":"69","author":"Eibl MM","year":"1987","journal-title":"Blood"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb05268.x"},{"key":"e_1_2_8_30_2","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1182\/blood.V64.1.308.308","article-title":"Diminished helper\/suppressor lymphocyte ratios and natural killer activity in recipients of repeated blood transfusions.","volume":"64","author":"Kaplan J","year":"1984","journal-title":"Blood"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1995.tb00344.x"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1996.tb01325.x"},{"key":"e_1_2_8_33_2","first-page":"545","article-title":"Antibody response to immunization in patients with haemophilia with and without evidence of HTLV\u2010III infection.","volume":"109","author":"Ragni MV","year":"1987","journal-title":"J Lab Clin Med"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2000.00386.x"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1989.tb04296.x"},{"key":"e_1_2_8_36_2","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood.V85.9.2337.bloodjournal8592337","article-title":"Randomized study of didanosine monotherapy and combination therapy with zidovudine in hemophilic and non\u2010hemophilic subjects with asymptomatic HIV\u20101 infection.","volume":"85","author":"Ragni MV","year":"1995","journal-title":"Blood"},{"key":"e_1_2_8_37_2","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1182\/blood.V84.6.2021.2021","article-title":"Identification of transforming growth factor\u2010\u03b2 as a contaminant in factor VIII concentrates: a possible link with immunosuppressive effects in hemophiliacs.","volume":"84","author":"Wadhha M","year":"1994","journal-title":"Blood"},{"key":"e_1_2_8_38_2","first-page":"12","article-title":"Hemophilia treatment in Massachusetts: trends of care and economic implications.","volume":"4","author":"Ewenstein B","year":"1999","journal-title":"Hemaware"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.440370.x"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199401063300108"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.440546.x"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.22.11851"},{"key":"e_1_2_8_43_2","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1182\/blood.V74.5.1618.1618","article-title":"Localization of epitopes of human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization.","volume":"74","author":"Scandella D","year":"1989","journal-title":"Blood"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.82.22.7728"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/46601"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.48.30191"},{"key":"e_1_2_8_47_2","doi-asserted-by":"crossref","first-page":"12481","DOI":"10.1016\/S0021-9258(18)98924-6","article-title":"Structural basis for the decreased procoagulant activity of human factor VIII compared to the porcine homolog.","volume":"265","author":"Lollar P","year":"1991","journal-title":"J Biol Chem"},{"key":"e_1_2_8_48_2","first-page":"275A.","article-title":"Folding of the C\u2010domain of factor VIII is essential for its secretion.","volume":"91","author":"Yamanaka K","year":"1999","journal-title":"Thromb Haemost"},{"key":"e_1_2_8_49_2","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1055\/s-0037-1614944","article-title":"Mutation at either Arg336 or Arg562 in factor VIII is insufficient for complete resistance to activated protein C (APC) \u2010mediated inactivation: implications for the APC resistance test.","volume":"79","author":"Amano K","year":"1998","journal-title":"Thromb Haemost"},{"key":"e_1_2_8_50_2","doi-asserted-by":"publisher","DOI":"10.1038\/381434a0"},{"key":"e_1_2_8_51_2","first-page":"1298","article-title":"Immunomodulation suppresses inhibitor formation in a muscle\u2010directed gene therapy in hemophilia B mice with a large F.IX gene deletion.","volume":"409","author":"Fields PA","year":"1999","journal-title":"Thromb Haemost"},{"key":"e_1_2_8_52_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.16.8789"},{"key":"e_1_2_8_53_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.4.1857"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2516.2001.00097.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2516.2001.00097.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2516.2001.00097.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T07:59:04Z","timestamp":1695801544000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2516.2001.00097.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1]]},"references-count":52,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2001,1]]}},"alternative-id":["10.1046\/j.1365-2516.2001.00097.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2516.2001.00097.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,1]]}}}